Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The company reported findings from one oral and two poster sessions, supporting the potential of these candidates in cancer treatment.
TNX-1700, a recombinant enzyme, demonstrated the ability to reduce inflammation and tumor progression in gastric cancer models, along with favorable pharmacokinetics. These results suggest its potential as a targeted therapy for gastric cancer, a disease with high unmet medical need. TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), showed promising in vitro activity, underscoring its potential as a cancer immunotherapy candidate either alone or in combination with other checkpoint inhibitors. BTLA is an immune checkpoint receptor that inhibits T-cell activation, and targeting it may enhance anti-tumor immune responses.
The AACR Annual Meeting is a premier venue for presenting cutting-edge cancer research, and Tonix's inclusion in multiple sessions highlights the significance of these findings. The data support the advancement of these programs toward clinical development. For more details, the full press release is available at https://ibn.fm/Oly6o.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace SymTouch and Tosymra. The company is also exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder.
In addition to its immuno-oncology pipeline, Tonix is advancing a range of immunology programs. These include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Investors can find the latest news and updates relating to TNXP in the company's newsroom at https://ibn.fm/TNXP.
